statistiche ricercatore

DE LERMA BARBARO, ANDREA

Distribuzione geografica

Continente	#
NA - Nord America	8.729
EU - Europa	5.408
AS - Asia	3.429
SA - Sud America	332
Continente sconosciuto - Info sul continente non disponibili	60
AF - Africa	47
OC - Oceania	12
Totale	18.017

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	8.442
IT - Italia	2.598
SG - Singapore	1.161
UA - Ucraina	959
CN - Cina	723
VN - Vietnam	546
TR - Turchia	389
SE - Svezia	379
HK - Hong Kong	372
FI - Finlandia	300
BR - Brasile	284
DE - Germania	283
FR - Francia	247
IE - Irlanda	206
CA - Canada	178
GB - Regno Unito	169
RU - Federazione Russa	131
IN - India	86
MX - Messico	47
BD - Bangladesh	46
NL - Olanda	27
JP - Giappone	26
PL - Polonia	26
ZA - Sudafrica	19
ES - Italia	17
IQ - Iraq	16
BE - Belgio	14
AR - Argentina	13
CO - Colombia	13
CR - Costa Rica	12
AT - Austria	11
LT - Lituania	10
NZ - Nuova Zelanda	9
PK - Pakistan	9
CH - Svizzera	8
JM - Giamaica	8
PY - Paraguay	8
SA - Arabia Saudita	8
CZ - Repubblica Ceca	7
GT - Guatemala	7
NG - Nigeria	7
SV - El Salvador	7
UZ - Uzbekistan	7
AE - Emirati Arabi Uniti	6
NI - Nicaragua	6
EG - Egitto	5
EU - Europa	5
HN - Honduras	5
KE - Kenya	5
MY - Malesia	5
TN - Tunisia	5
LB - Libano	4
PH - Filippine	4
PR - Porto Rico	4
RS - Serbia	4
TT - Trinidad e Tobago	4
VE - Venezuela	4
AU - Australia	3
CW - ???statistics.table.value.countryCode.CW???	3
DK - Danimarca	3
DZ - Algeria	3
GP - Guadalupe	3
ID - Indonesia	3
KR - Corea	3
MA - Marocco	3
PE - Perù	3
CL - Cile	2
EC - Ecuador	2
GR - Grecia	2
KH - Cambogia	2
MD - Moldavia	2
NP - Nepal	2
OM - Oman	2
PA - Panama	2
UY - Uruguay	2
AZ - Azerbaigian	1
BB - Barbados	1
BG - Bulgaria	1
BH - Bahrain	1
BS - Bahamas	1
BY - Bielorussia	1
DO - Repubblica Dominicana	1
EE - Estonia	1
GL - Groenlandia	1
GY - Guiana	1
IL - Israele	1
JO - Giordania	1
MO - Macao, regione amministrativa speciale della Cina	1
MT - Malta	1
PS - Palestinian Territory	1
PT - Portogallo	1
SY - Repubblica araba siriana	1
TH - Thailandia	1
TW - Taiwan	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	17.966

Salva come PNG Salva come JPEG

Città	#
Milan	1.848
Ashburn	1.155
San Jose	836
Jacksonville	726
Singapore	660
Chandler	529
Fairfield	453
Council Bluffs	395
Hong Kong	362
Woodbridge	355
Wilmington	260
Princeton	245
Beijing	233
Dallas	231
Ann Arbor	229
Izmir	229
Nyköping	216
Dublin	206
Dearborn	194
Seattle	194
Houston	183
The Dalles	165
Dong Ket	155
Boardman	147
Rome	136
Cambridge	134
Toronto	121
Lauterbourg	116
New York	106
Como	103
San Mateo	92
Chicago	87
Los Angeles	85
Santa Clara	68
Ho Chi Minh City	67
São Paulo	61
San Diego	56
Hanoi	50
Helsinki	50
Orem	47
Guangzhou	39
Ogden	38
Munich	37
Chennai	36
Düsseldorf	29
London	29
Mexico City	27
Verona	24
Warsaw	23
Manchester	22
Pune	22
Tokyo	22
Hefei	21
Brooklyn	17
Turku	16
Atlanta	15
Montreal	15
Nanjing	15
Shanghai	15
Johannesburg	13
Amsterdam	12
Brussels	12
Kunming	12
San Francisco	12
Boston	11
Da Nang	11
Denver	11
Washington	11
Frankfurt am Main	10
Fuzhou	10
Hangzhou	10
Phoenix	10
Stockholm	10
Buffalo	9
Haiphong	9
North Bergen	9
Norwalk	9
San José	9
Shenzhen	9
St Petersburg	9
Charlotte	8
Jinan	8
Miami	8
Naples	8
Poplar	8
Redwood City	8
Zhengzhou	8
Abuja	7
Baghdad	7
Christchurch	7
Curitiba	7
Guatemala City	7
Mumbai	7
New Delhi	7
Ponte Lambro	7
Queens	7
Raleigh	7
Varese	7
Auburn Hills	6
Bogotá	6
Totale	12.410

Salva come PNG Salva come JPEG

Nome	#
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4(+) T lymphocytes for immunotherapy	240
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells	225
The MHC class II transactivator: prey and hunter in infectious diseases	219
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection and specific anti-tumor memory.	215
Surface protein components from entomopathogenic nematodes and their symbiotic bacteria: effects on immune responses of the greater wax moth, Galleria mellonella (Lepidoptera: Pyralidae)	215
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent antitumor preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.	214
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific anti-tumor memory	214
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a TH1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory	213
Divergent evolution in the mechanisms controlling major histocompatibility complex class II gene transcription in mouse and human	210
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells.	201
Inflammatory cues acting on the adult intestinal stem cells and the early onset of cancer (Review)	198
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1b molecules after bacterial phagocytosis	198
The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication	187
New strategies of mammary cancer vaccination	187
In Vivo Effects of A Pro-PO System Inhibitor on the Phagocytosis of Xenorhabdus Nematophila in Galleria Mellonella Larvae	186
The MHC class II transactivator (CIITA): a physiologic inhibitor of HIV1 and HTLV2 retroviral infections	178
The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2	177
Block of Stat-1 activation in macrophages, undergoing bacterial phagocytosis causes CIITA reduced transcription and consequent impaired antigen presentation	175
Tumor rejection and anti-tumor memory to cancer cells of different histotype genetically modified to express CIITA-driven autologous MHC class II genes. A new strategy of anti-tumor vaccination and tumor immunotherapy.	174
MHC class II gene regulation: some historical considerations on a still ontogenetic and phylogenetic puzzle	173
TPA-mediated down-regulation of MHC class II gene expression in human macrophage precursors by destabilization of the MHC-II transactivator (CIITA) mRNA	170
Analysis of microchimerism in thyroid autoimmune diseases	169
A new strategy of tumor vaccination based on mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA	169
HIV-1 Tat mutants in the cysteine-rich region down-regulate HLA class II expression in T lymphocytic and macrophage cell lines	168
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy	166
Analysis of a combined immunodeficiency patient with defect in MHCII expression (BLS) reveals the presence of several mutant isoforms of RFXANK mRNA	164
Apoptotic DNA binds to HLA class II molecules inhibiting antigen presentation and partecipatine in the development of anti-inflammatory functional behavior of phagocytic macrophages	163
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1B molecules after mycobacterial phagocytosis	163
Distinct regulation of HLA class II and class I cell surface expression in THP-1 macrophage cell line after bacterial phagocytosis	162
Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR	162
CIITA-driven MHC-II+ tumor cells: preventive vaccines and superior generators of anti-tumor CD4+ T lymphocytes for immunotherapy.	158
The HLA class II transcriptional activator (CIITA) blocks the function of HIV-1 Tat and inhibits viral replication	158
Physiologic target of the Air-1 trans-activator revealed by stable transfection assay	158
The complex liaison between cachexia and tumor burden	157
Antitumor vaccines and immunotherapeutic strategies based on CIITA-driven MHC class II espression in cancer cells.	156
CIITA blocks the function of HIV-1 Tat by competing for cyclin T1 and inhibits viral replication	156
The molecular basis of the inhibition of HTLV-2 retroviral replication by the MHC class II transactivator (CIITA)	156
The history of discovery of Interleukin-1: A fundamental cytokine of the innate immune response	154
MHC immunoevasins: protecting the pathogen reservoir in infection	154
Efficient antigen presentation and T cell activation by MHC class II molecules of CIITA-transfected epatocarcinoma cells	154
CIITA reduced transcription as the cause of HLA class II down-modulation in human macrophages during bacterial phagocytosis	154
The MHC class II transactivator is a strong physiologic antagonist of HIV-1 replication	152
Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells	152
Inflammation, inflammatory cells and angiogenesis: decisions and indecisions	151
CIITA-driven MHC class II expressing tumor cells of distinct hystotype act as a potent antitumor vaccine and as a superior generators of tumor-specific CD4+ T lymphocytes for immunotherapy.	151
The immunological basis of therapy-induced antitumor vaccination by targeting Tumor Necrosis Factor a to tumor vessels in combination with melphalan	151
HTLV2 influence on pathways regulating proliferation and death in B cell line BJAB	151
Inhibition of Human T-Cell Leukemia virus type 2 (HTLV-2) replication by the suppressive action of CIITA and NF-Y	150
The MHC class II transactivator, CIITA, blocks the transcriptional activity of both HTLV-2 Tax-2 and HTLV-1 Tax-1	150
Control of tumor growth in vivo by gene therapy with the MHC class II transactivator (CIITA)	150
Espressione delle molecole HLA di classe II in cellule di epatocarcinoma classe II negative dopo trasfezione del transattivatore CIITA. Acquisizione della capacità di processare e presentare l'antigene	149
The MHC class II transactivator (CIITA): a physiologic inhibitor of HTLV-2 retroviral infection.	149
CIITA reduced transcription as the cause of HLA class II downregulation in human macrophages during bacterial phagocytosis	148
Inhibition of human T cell leukemia virus type 2 (HTLV-2) replication by the suppressive action of class II transactivator and nuclear factor Y	148
A new strategy of tumor vaccination based on tumor cells transduced with the MHC class II transactivator CIITA	148
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent antitumor preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions	148
The HLA class II transcriptional activator (CIITA) blocks the function of HIV-1 Tat and inhibits viral replication	146
Therapy-induced antitumor vaccination by targeting tumor necrosis factor  to tumor vessels in combination with melphalan	146
The utility of introducing a measurement of tumor burden for a better assessment of cancer cachexia.	146
Neutrophil and Natural Killer Cell Interactions in Cancers: Dangerous Liaisons Instructing Immunosuppression and Angiogenesis	146
Tumor treatment by TNF-alpha targeted to tumor vessels and melphalan induces strong adaptive immune response, protection from tumor growth and anti-tumor memory.	143
Evidence for a specific post-transcriptional mechanism controlling the expression of HLA-DQ, but not -DR and -DP, molecules	142
Regulation of HLA antigen expression in HIV infected cells	140
Phagocytosis of bacteria in macrophages causes a reduced IFN-g-dependent transcription of CIITA through a block of STAT-1 phosphorylation	138
HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA. Acquisition of antigen processing and presentation capacity.	137
Inibizione della replicazione virale di HIV-1 e HTLV-2 da parte di CIITA il regolatore trascrizionale dell'espressione dell'HLA-II	137
Control of mammary adenocarcinoma growth in vivo by gene therapy with the MHC class II transactivator CIITA	134
Characterization of an epigenetic variant lacking MHC-II inducibility by IFN-g in the promyelocytic cell line THP-1	134
The AIR-1 locus encoded HLA class II transcriptional activator (CIITA) inhibits HIV-1 replication by blocking the function of HIV-1 Tat	134
Metabolic Rewiring in the Tumor Microenvironment to Support Immunotherapy: A Focus on Neutrophils, Polymorphonuclear Myeloid-Derived Suppressor Cells and Natural Killer Cells	134
Constitutive and inducible expression of HLA class II genes in normal cells is under the control of the AIR-1-encoded CIITA trans-activator	133
Evidence for a specific post- transcriptional mechanism controlling the expression of HLA-DQ, but not DR and DP molecules	132
Methylation of CIITA promoter IV causes loss of HLA-II inducibility by gamma-IFN in promyelocytic cells	131
The MHC class II transactivator (CIITA): a "physiologic" drug against HIV-1 replication	131
The replication of HTLV-2 and the expression of HLA class II transcriptional activator (CIITA) are inversely correlated	130
Innate and adaptive immune function of the MHC class II transactivator, CIITA, against human tumor retroviruses HTLV-2 and HTLV-1	129
Therapy-induced antitumor vaccination by targeting TNFa to tumor vessels in combination with melphalan	128
Reduced expression of the AIR-1 gene product CIITA as the cause of HLA class II down-modulation in normal human macrophages during bacterial phagocytosis	128
Experimental therapeutic approaches to adenocarcinoma: the potential of tumor cells engineered to express MHC class-II molecules combined with naked DNA interleukin-12 gene transfer	127
Regulation of HLA antigen expression in phagocytes with mycobacteria	127
La presentazione antigenica su molecole di II classe HLA è profondamente alterata in seguito a fagocitosi batterica	125
Regolazione dell'espressione dei geni del Complesso Maggiore di Istocompatibilità HLA e di CD4 in cellule infettate da HIV: effetto di TAT	124
Effetto del gene TAT di HIV sulla regolazione dell'espressione delle molecole HLA e CD4	124
Regulation of HLA antigen expression in phagocytes treated with mycobacteria	124
Tumor vaccination by CIITA-mediated MHC-II-expressing neoplastic cells	123
Expression of AIR-1/CIITA transactivator in B cell x plasmacytoma somatic cell hybrids restores HLA-DR and -DP expression, but not -DQ	123
The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in differentiating myelomonocytic cells.	122
Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan	122
Irradiated CIITA-positive mammary adenocarcinoma cells act as potent anti-tumor preventive vaccine by inducine tumor-specific CD4+ T cell priming and CD8+ T cell effector functions	122
Imaging guided percutaneous microwave ablation of tumors.	122
Irradiated CIITA-positive mammary adenocarcinoma cells act as effective tumor cell vaccine inducing both tumor-specific CD4+ and CD8+ T immune responses and tumor rejection upon challenge.	121
Inhibition of HTLV-2 viral replication by the MHC class II transcriptional activator (CIITA)	121
HLA class II-dependent antigen presentation is deeply impaired in macrophage reservoir of infection	120
The molecular and cellular basis of tumor rejection after vaccination with mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA	118
Higly stable oligomerization forms of HIV-1 Tat detected by Monoclonal antibodies and requirement of monomeric forms for the transactivating function of the HIV-1 LTR	117
HLA-DQ expression is differently regulated from -DR and -DP	117
The immunological basis of tumor rejection and anti-tumor memory to neoplasias of different histotype genetically modified to express CIITA-driven autologous MHC class II genes.	115
Control of tumor growth in vivo by gene therapy with the MHC class II transactivator CIITA	115
Reduced expression of the AIR-1 gene product CIITA as the cause of HLA class II down modulation in normal human macrophages during bacterial phagocytosis.	115
The complex liaison between vulnerability to cachexia and tumor burden.	115
Totale	15.276

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	70.906
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	70.906

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	721	0	0	0	111	22	19	41	95	53	128	91	161
2022/2023	1.408	151	66	123	167	97	319	0	188	173	37	51	36
2023/2024	2.818	452	438	505	488	499	220	24	25	104	17	2	44
2024/2025	1.712	13	47	320	32	84	70	79	86	221	109	133	518
2025/2026	4.114	307	235	118	553	429	279	1.019	256	393	254	139	132
2026/2027	1.680	79	202	699	700	0	0	0	0	0	0	0	0
Totale													18.017